LAG3 antibody (full length)

Catalog No. ABIN7878542

This Mouse Monoclonal antibody specifically detects LAG3 in ELISA. It exhibits reactivity toward Human.

Quick Overview for LAG3 antibody (full length) (ABIN7878542)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This LAG3 antibody is un-conjugated

Application: ELISA

Grade: Carrier-free

Clone: LAG3-3261

Product Details anti-LAG3 Antibody

Binding Specificity: full length

Purpose: LAG3 Antibody / Lymphocyte activation gene 3 / CD223 (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: A recombinant full-length human LAG3 protein was used as the immunogen for this LAG3 antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the LAG3 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the LAG3 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: LAG3

Background: LAG-3 (also called CD223) is a high affinity MHC class II ligand present on the surface of CD4+CD8+ T cells and NK cell, with shared homology in structure to CD4 Molecules. It has a glutamic acid-proline (EP) repetitive sequence found in other functionally distinct mammalian, parasitic, and bacterial proteins that may influence a conserved biological function. LAG-3+CD4+CD8+ T cells can associate with the T cell receptor (TCR) and downregulate TCR signaling in vitro. LAG-3 inhibits CD4-dependent T cell function via its cytoplasmic domain. LAG-3 Lys-468 within a conserved 'KIEELE' motif is essential for interaction with downstream signaling molecules. Furthermore, as a checkpoint inhibitor target, it may be superior to CTLA-4 and PD-1 since both antibodies only activate effector T-cells, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints